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sitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We
assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radio-
therapy in patients with non-small cell lung carcinoma (NSCLC) and investigated its effect
on tumour hypoxia.
Methods: This was a 3 þ 3 dose escalation and dose expansion phase I trial in patients with
advanced NSCLC. Buparlisib dose levels were 50 mg, 80 mg and 100 mg once daily orally for
2 weeks, with palliative thoracic radiotherapy (20 Gy in 5 fractions) delivered during week 2.f Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom. Fax: þ44 1865 617318.
cology.ox.ac.uk (G.S. Higgins).
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D.R. McGowan et al. / European Journal of Cancer 113 (2019) 87e9588Tumour hypoxic volume (HV) was measured using 18F-fluoromisonidazole positron-emission
tomographyecomputed tomography at baseline and following 1 week of buparlisib.
Results: Twenty-one patients were recruited with 9 patients evaluable for maximum tolerated
dose (MTD) analysis. No dose-limiting toxicity was reported; therefore, 100 mg was declared
the MTD, and 10 patients received this dose in the expansion phase. Ninety-four percent of
treatment-related adverse events were grade 2 with fatigue (67%), nausea (24%) and
decreased appetite (19%) most common per patient. One serious adverse event (grade 3 hy-
poalbuminaemia) was possibly related to buparlisib. No unexpected radiotherapy toxicity
was reported. Ten (67%) of 15 patients evaluable for imaging analysis were responders with
20% median reduction in HV at the MTD.
Conclusion: This is the first clinical trial to combine a PI3K inhibitor with radiotherapy in
NSCLC and investigate the effects of PI3K inhibition on tumour hypoxia. This combination
was well tolerated and PI3K inhibition reduced hypoxia, warranting investigation into
whether this novel class of radiosensitisers can improve radiotherapy outcomes.
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Radiotherapy is used in half of patients with cancer [1];
however, tumour response and treatment efficacy are
highly variable. In locally advanced non-small cell lung
carcinoma (NSCLC), outcomes following standard
radical (chemo)radiotherapy remain exceptionally poor
with 5-year overall survival only in the region of 15% [2].
It is well recognised that suboptimal locoregional con-
trol contributes to such poor outcomes [3] and that the
development of novel radiosensitisers represents an
unmet clinical need for this patient group.
Intracellular signal transduction pathways are known
to play an important role in determining tumour
response to radiation, thus providing opportunity for
developing radiosensitisers [4]. In particular, the well-
studied EGFR/Ras/PI3K/Akt pathway appears to be
pivotal. Aberrant activation of this pathway is common
in many tumour types, including NSCLC, and correlates
with poor clinical outcomes after radiotherapy [5e7].
In vitro radiosensitivity studies demonstrate that acti-
vation of Ras, PI3K or Akt results in marked resistance
of tumour cell lines to radiation, whereas inhibition
improves response [8].
The importance of the EGFR/Ras/PI3K/Akt
pathway in modifying the tumour microenvironment to
alter radiation response has also become apparent,
specifically with regard to oxygenation. In vivo experi-
ments have shown that inhibitors of EGFR, Ras,
PI3K and Akt result in marked ‘normalisation’ of
tumour microvasculature with durable increases in
perfusion and alleviation of tumour hypoxia [9,10].
Hypoxic regions are a common feature of solid tumours
and result from an imbalance between high oxygen de-
mand and poor oxygen delivery because of dysfunc-
tional tumour vasculature [11]. Hypoxia is associated
with an aggressive tumour phenotype and treatment
resistance, which is especially pertinent for radiotherapy[12]. There is therefore significant interest in developing
hypoxia modifiers as radiosensitisers and the ability of
PI3K inhibitors to reduce tumour hypoxia represents a
novel class of agents for this purpose. In vivo experi-
ments have demonstrated that PI3K inhibition results in
significant tumour growth delay after radiation because
of vascular remodelling which is independent and syn-
ergistic to increasing intrinsic radiosensitivity [13].
Buparlisib (BKM120) (Novartis International AG,
Switzerland) is an oral pan class 1 PI3K inhibitor. In
xenografts, buparlisib reduces tumour hypoxia through
rapid vascular remodelling [13]. In vitro studies have also
demonstrated that buparlisib inhibits tumour mito-
chondrial oxygen consumption, thereby further
contributing to hypoxia modification [14]. Clinical
studies using buparlisib have been conducted in a range
of tumour types, with established favourable pharma-
cokinetics, acceptable toxicity and mixed response rates
[15e17]. Although buparlisib has significant potential to
improve radiotherapy response, no previous trials have
combined this agent with radiation.
We therefore conducted a phase I clinical trial of
buparlisib with thoracic radiotherapy. The primary aim
of this study was to investigate the safety and maximum
tolerated dose (MTD) of buparlisib in combination with
palliative radiotherapy. Palliative radiotherapy was
chosen as there were no previous reports of combining
this agent with radiation and because of the significant
toxicity of radical radiotherapy in NSCLC. This study
also investigated the effect of buparlisib on tumour
hypoxia, using 18F-fluoromisonidazole (FMISO) posi-
tron-emission tomographyecomputed tomography
(PET-CT). The use of radiolabelled tracers such as
FMISO has become the most widely used method for
the clinical study of tumour hypoxia. This non-invasive
method correlates with other measures of hypoxia, is
highly reproducible and functions as a predictive
biomarker of radiotherapy outcomes [18e20].
D.R. McGowan et al. / European Journal of Cancer 113 (2019) 87e95 89Our findings provide clinical evidence for the safety
of combining PI3K inhibition with thoracic radio-
therapy and for the effect of this class of agents on
tumour hypoxia in NSCLC.2. Materials and methods
2.1. Study design
This was a single-centre (Oxford Cancer Centre), open-
label, dose escalation and expansion phase I clinical trial
(EudraCT number: 2012-003762-40). All patients pro-
vided written consent and trial conduct complied with
the Declaration of Helsinki. Ethical approval was ob-
tained from National Research Ethics Service Com-
mittee South Central Oxford B (12/SC/0674).
Dose escalation of oral once daily (OD) buparlisib
followed a standard 3 þ 3 design with three pre-
determined dose cohorts: cohort 1 50 mg, cohort 2
80 mg and cohort 3 100 mg. Primary end-points assessed
the safety and determined the MTD of buparlisib when
combined with palliative thoracic radiotherapy. The
MTD was defined as the dose at which no more than
0 of 3 patients or 1 of 6 patients experienced a dose
limiting toxicity (DLT). Dose escalation was not
permitted beyond 100 mg OD as this dose has previ-
ously been established as the single agent MTD [15].
Once the MTD was determined, this dose was used in an
expansion cohort of 6 patients with data from all trial
patients used to investigate the effect of buparlisib on
tumour hypoxia and perfusion after 1 week of treatment
(secondary trial end-points). The trial schema is shown
in Fig. 1.
2.2. Patients
Patients aged 18 years with life expectancy of 16
weeks, Eastern Cooperative Oncology Group Perfor-
mance Status of 0e2, histologically confirmed advancedFig. 1. Trial schema. D, day; FMISO, 18F-fluoromisonidazole; PET,
raphy; OD, once daily; MTD, maximum tolerated dose.stage NSCLC and a thoracic lesion requiring palliative
radiotherapy were eligible. Key exclusion criteria were
uncontrolled central nervous system metastases, poorly
controlled diabetes mellitus, psychiatric illness, cardiac
disease or other malignancy (other than NSCLC) in the
last three years. Anti-cancer therapy within 28 days;
previous thoracic radiotherapy or exposure to PI3K,
mTOR, or Akt inhibitors was not permitted. Full details
of the study design including eligibility criteria can be
found in the trial protocol provided as Supplementary
information.
2.3. Treatment regimen
Oral buparlisib was administered OD for 14 days with
palliative thoracic radiotherapy delivered during the
second week. For radiotherapy planning, patients un-
derwent CT simulation with gross tumour volume out-
lined and 2 cm margin added for field edge. Treatment
was delivered using parallel 6 or 15 MV photon beams,
and 20 Gy in 5 daily fractions was prescribed according
to International Commission on Radiation Units
(ICRU 62) guidance. As palliative radiation was used,
no dose constraints were specified.
2.4. Assessments
Adverse events (AEs) were graded according to the
National Cancer Institute’s Common Terminology
Criteria (NCI CTCAE version 4.0). DLT was defined as
follows: grade 3 non-haematological toxicity
(excluding nausea, vomiting or diarrhoea) that required
hospitalisation or which did not resolve to grade 2
within 7 days, grade 3 nausea, vomiting or diarrhoea
that persisted for >48 h, grade 3 pneumonitis, grade
4 haematological toxicity and grade 3 mood change if
baseline score was 2 in the self-reported PHQ-9 or
GAD-7 mood questionnaire or grade 2 mood change
if baseline score was 1. DLT was considered if toxicitypositron-emission tomography; pCT, perfusion computed tomog-
Fig. 2. Consort diagram. FMISO, 18F-fluoromisonidazole; MTD, maximum tolerated dose; PET, positron-emission tomography; pCT,
perfusion computed tomography.
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radiotherapy.
Tumour response was the change in tumour hypoxic
volume (HV) as detected by FMISO PET-CT per-
formed at baseline and on day 8 of buparlisib, before
radiotherapy. Patients were imaged using a Discovery
690 or 710 PET-CT scanner (GE Healthcare). 370 MBq
of FMISO (University of Cambridge, UK) was injected
and a 10-min image acquired 4 h after injection. CT
was performed for localisation and PET attenuation
correction. Tumour outlining was performed by an
experienced PET-CT radiologist. Background mean
standardised uptake (SUVmean) was obtained by out-
lining blood in the descending aorta. To determine HV,
voxel-by-voxel SUVs were divided by the background
SUVmean providing tumour-to-blood ratio (TBR)
values, and voxels with TBR 1.4 were classified hyp-
oxic, as previously described [21]. Volumes of hypoxic
voxels before and after buparlisib were compared and
10% reduction in HV was defined as a response. This
cutoff was based on reproducibility test-retest data for
FMISO imaging [20] and used the minimum detectablechange (MDC) method [22]. Okamoto et al. showed a
mean difference of 2.7% and SD 14% in tumour-to-
muscle (TMR) volumes from FMISO scans repeated
within 48 h (n Z 9, excluding two patients with TMR
volumes <1.5 mL) [20]. MDC is the smallest change at
95% confidence interval and is defined as the standard
error (4.7) multiplied by 1.96, giving 9.2%. Our 10%
threshold was ratified by the University’s independent
Early Phase Trial Oversight Committee in combination
with an external radiologist.
Changes in tumour perfusion were also investigated
using perfusion CT (pCT) imaging. The pCT technique
used is provided as Supplementary methodology.2.5. Statistical analysis
Patients were evaluable for DLT analysis after 14 days
of buparlisib if they completed 56 days of evaluation or
withdrew early after experiencing DLT. Patients who
withdrew early for other reasons were deemed non-
evaluable and were replaced. All patients who received
D.R. McGowan et al. / European Journal of Cancer 113 (2019) 87e95 91a dose of buparlisib were included in the safety anal-
ysis, for which descriptive statistics were used.
Secondary end-point analysis included all patients
who had an interpretable pair of FMISO PET-CT scans.
Patients with insufficient baseline HV (<1.5 mL) to
reliably measure change were excluded. The number of
hypoxia or perfusion responders, median response per
cohort and waterfall plots were used to summarise the
data. Analysis was undertaken using Stata v15.0 (Sta-
taCorp, College Station, TX).3. Results
From June 2013 to August 2017, 21 patients were
recruited. Eleven patients were registered for dose
escalation with 9 evaluable for DLT analysis. Ten pa-
tients were registered during dose expansion, and in
total, 15 patients were evaluable for tumour response
analysis. The CONSORT diagram is shown in Fig. 2,
and baseline patient characteristics are summarised in
Table 1.
All 21 patients started buparlisib and 19 patients
started radiotherapy. Fifteen (71%) patients had full
compliance with treatment. Three patients discontinued
treatment because of AEs (described below), 1 patient
accidentally missed a dose of buparlisib, 1 patientTable 1
Baseline characteristics.
Characteristics Dose escalation phase
Cohort 1 (n Z 4) Cohort 2 (n
Age [years] 64 (58e77) 72 (63e75)
Gender
Male 50 (2) 50 (2)
Female 50 (2) 50 (2)
Stage of disease
IV 100 (4) 100 (4)
ECOG performance status
0 0 (0) 0 (0)
1 100 (4) 100 (4)
Tumour volume [mL]a 111 (13e510) 135 (29e204
Histology
Adenocarcinoma 75 (3) 25 (1)
Squamous cell 25 (1) 75 (3)
Previous treatment
Chemotherapy 50 (2) 50 (2)
Surgical treatment 0 0
Extrathoracic radiotherapy 0 25 (1)
Predominant clinical indication for radiotherapy
Chest pain 25 (1) 0
Bronchial obstruction 75 (3) 25 (1)
Cough 0 25 (1)
Superior vena cava obstruction 0 25 (1)
Solitary site of progression 0 25 (1)
Haemoptysis 0 0
Left atrium invasion 0 0
Brachial plexus invasion 0 0
Data are median (range) or % (number).
ECOG, Eastern Cooperative Oncology Group.
a Tumour volume data were only available for patients evaluable for thediscontinued treatment because of disease progression
and 1 patient was replaced because of FMISO produc-
tion failure.3.1. MTD and safety assessment
No DLT was reported; therefore, buparlisib 100 mg OD
was declared as the MTD. The safety analysis results are
summarised in Table 2. In total, 114 AEs were experi-
enced by 20 of 21 patients of which 103 (90%) were
grade 2. One patient in the expansion cohort dis-
continued treatment because of worsening long-standing
abdominal pain (unrelated to treatment). 94% of all AEs
with any relation to treatment were grade 2 with only
three grade 3 AEs deemed possibly related to treat-
ment (2 fatigue and 1 hypoalbuminaemia). Most com-
mon treatment-related AEs per patient were fatigue
(67%), nausea (24%) and decreased appetite (19%).
Five AEs, all grade 1, were specifically related to
radiotherapy and included skin reaction in 3 patients
and fatigue and cough in another patient. There was no
reported acute oesophagitis or pneumonitis.
Four patients experienced serious adverse events.
One patient (cohort 2) discontinued treatment due to
grade 5 lower limb ischaemia, which was deemed unre-
lated to treatment due to long-standing vascular diseaseExpansion
phase (n Z 10)
Total (n Z 21)
Z 4) Cohort 3 (n Z 3)
68 (68e72) 68 (52e78) 69 (52e78)
33 (1) 20 (2) 33 (7)
67 (2) 80 (8) 67 (14)
100 (3) 100 (10) 100 (21)
33 (1) 50 (5) 29 (6)
67 (2) 50 (5) 71 (15)
) 54 (40e219) 99 (8e250) 101 (8e510)
33 (1) 60 (6) 52 (11)
67 (2) 40 (4) 48 (10)
33 (1) 70 (7) 57 (12)
0 60 (6) 29 (6)
0 30 (3) 19 (4)
33 (1) 40 (4) 29 (6)
0 10 (1) 24 (5)
0 40 (4) 24 (5)
0 0 5 (1)
0 0 5 (1)
33 (1) 0 5 (1)
33 (1) 0 5 (1)
0 10 (1) 5 (1)
imaging analysis.
D.R. McGowan et al. / European Journal of Cancer 113 (2019) 87e9592and symptoms of acute ischaemia preceded starting
buparlisib. One patient (cohort 3) developed grade 3
lung infection (unrelated to treatment) and hypo-
albuminaemia (possibly related to buparlisib) and dis-
continued treatment. Two patients (cohorts 1 and 2)
experienced grade 3 lung infection (unrelated to
treatment).
3.2. Tumour response to buparlisib
Fifteen patients were evaluable for tumour hypoxia
analysis. As shown by the waterfall plot in Fig. 3, 10
(67%) of 15 patients were responders. Table 3 summa-
rises the hypoxia response data. All cohort 1 patients
were non-responders with 7% median HV increase. All
cohort 2 patients were responders with 18% median HV
decrease. In cohort 3 and the expansion cohort, 7 (77%)
of 9 patients were responders with 20% median HV
decrease. No correlation between tumour size andTable 2
Adverse events.
Parameter Dose group
Cohort 1 [50 mg] (n Z 4) Coh
Total number of AE episodesb 19 17
Patients with
AEs 4 (100) 4 (10
Grade  3 AEs 1 (25) 2 (50
SAEs 1 (25) 2 (50
Patients discontinued treatment because of
AEs 0 0
SAEs 0 1 (25
Patients experiencing treatment-related AEsc
Fatigue 2 (50) 3 (75
Nausea 1 (25) 1 (25
Decreased appetite 1 (25) 0
Constipation 0 0
Radiotherapy skin reaction 1 (25) 0
Rash 0 0
Altered/depressed mood 0 0
Dyspepsia 0 1 (25
Hiccups 0 0
Oral candidiasis 1 (25) 0
Headache 0 1 (25
Weight loss 0 0
Stomatitis 0 0
Personality change 0 0
Dry skin 0 0
Hyperglycaemia 0 0
Hypophosphatemia 0 0
Vomiting 0 0
Cough 0 0
Nightmare 0 0
Total number of treatment-related AEs 6 6
Patients experiencing treatment-related SAEs
Hypoalbuminaemia 0 0
Data are patient number (%).
AE, adverse event; SAE, serious adverse event.
a Cohort 3 includes patients in the dose escalation and expansion phases
b AE episodes are shown only once per patient and if an AE occurrence w
AE which was present at baseline increased during study participation.
c Shown are AEs of all grades with possible, probable or definite relatioresponse was observed (Supplementary Fig. S1). Fig. 4
shows representative examples of FMISO PET-CT im-
ages for an expansion cohort patient.
pCT results are shown as supplementary data (Tables
S1 and S2).4. Discussion
We demonstrate that buparlisib, a pan class 1 PI3K
inhibitor, is well tolerated with palliative thoracic
radiotherapy and that this agent rapidly reduces tumour
hypoxia.
Although in our study a palliative dose of radiation
was used, the lack of any unexpected radiotherapy
toxicity reported is encouraging for the safe combina-
tion of this class of agent with radical doses of radiation.
Pre-clinical data demonstrate that PI3K inhibition
radiosensitises tumours, at least in part, by alleviatingTotal (n Z 21)
ort 2 [80 mg] (n Z 4) Cohort 3a [100 mg] (n Z 13)
78 114
0) 12 (92) 20 (95)
) 4 (31) 7 (33)
) 1 (8) 4 (19)
1 (8) 1 (5)
) 1 (8) 2 (10)
) 9 (69) 14 (67)
) 3 (23) 5 (24)
3 (23) 4 (19)
3 (23) 3 (14)
3 (23) 4 (19)
4 (31) 4 (19)
3 (23) 3 (14)
) 1 (8) 2 (10)
2 (15) 2 (10)
0 1 (5)
) 0 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
1 (8) 1 (5)
41 53
1 (8) 1 (5)
.
as temporally associated with study participation, or if the grade of an
n to treatment with buparlisib and/or radiotherapy.
Fig. 3. Waterfall plot of change in tumour hypoxic volume. Per-
centage change of tumour hypoxic volume per patient after 7 days
of buparlisib treatment. A 10% reduction in hypoxic volume
(dotted line) was classified a positive response. C1, cohort 1 (50 mg
OD); C2, cohort 2 (80 mg OD); C3, cohort 3 (100 mg OD);
FMISO, 18F-fluoromisonidazole; TBR, tumour-to-blood FMISO
uptake ratio (1.4).
Fig. 4. Example of tumour hypoxic response. FMISO PET-CT
images for one patient in the expansion cohort before (A) and
after (B) buparlisib treatment. PET images are fused with the
corresponding CT and displayed on a tumour-to-blood uptake
ratio (TBR) colour scale. Red regions depict a TBR greater than
1.4, indicating hypoxia, and no visible PET tracer uptake depicts a
TBR below 1, indicating normoxia. In this case, there was a 42%
reduction in tumour hypoxic volume after buparlisib. FMISO,
18F-fluoromisonidazole; PET, positron-emission tomography; CT,
computed tomography.
D.R. McGowan et al. / European Journal of Cancer 113 (2019) 87e95 93tumour hypoxia [13]. As hypoxia is predominantly a
tumour-specific phenomenon, in principle, such agents
are expected to preferentially radiosensitise tumours, as
compared with normal tissues.
Trial accrual was challenging for numerous reasons.
Patients with metastatic NSCLC requiring palliative
radiotherapy were generally unwell with poor perfor-
mance status and many were therefore ineligible for the
study. Commonly, radiotherapy was indicated urgently
and thus trial participation was clinically inappropriate.
The high rate of AEs experienced by patients reflects this
borderline fit and deteriorating patient group. The
increasing use of targeted treatments for advanced
NSCLC was a further challenge to recruitment, as was
the fact that this was a single-centre study.
Despite the relatively small size of our study, the
observation that buparlisib reduces tumour hypoxia
supports pre-clinical data and therefore represents an
important clinical proof-of-principle for this class of
agents. The absence of such studies in the development of
hypoxia modifiers previously may explain why numerous
clinical trials have failed to demonstrate improvement in
radiotherapy outcomes. A lack of sufficiently validatedTable 3
Summary of FMISO PET-CT results.
Cohort Number (%) of
responders per cohort
TBR >
First sc
Median
Cohort 1 (n Z 3) 0 44.4 [0
Cohort 2 (n Z 3) 3 (100) 51.3 [1
Cohort 3 (n Z 9) 7 (77) 33.1 [6
Overall (n [ 15) 10 (67) 40.4 [3
Data are number (%) or median (IQR). Cohort 3 includes patients in the
FMISO, 18F-fluoromisonidazole; PET, positron-emission tomography; TBhypoxia biomarkers to enable selection of patients who
would benefit from hypoxia treatment is further contrib-
utory. For example, in head and neck cancer, the hypoxia-
targeting agents nimorazole and tirapazamine may have
improved radiotherapy outcomes if predictive hypoxia
biomarkers were used to select patients [23,24]. Therefore,
to further develop PI3K inhibitors as radiosensitisers, it is
important to also develop and incorporate hypoxia bio-
markers into future study design.
As our data demonstrate a reduction in hypoxia after
PI3K inhibition, it is hoped that combining such agents
with radiotherapy may improve outcomes. To establish
this, studies in the radical radiotherapy setting are
required. As FMISO PET relies on tracer accumulation
in viable tissues with oxygen tensions significantly below
that at which radioresistance becomes a feature [25], it is1.4 volume
an
[IQR]
Second scan
Median [IQR]
% change
Median [IQR]
.4 239] 47.6 [0.4 233] 7.1 [2.5 14.3]
.3 99.5] 42.2 [1.1 75.6] 17.6 [24.1 e16.7]
.9 43.7] 25.4 [4.9 42.0] 19.9 [41.9 e14.6]
.3 67.5] 27.6 [3.5 52.5] L16.8 [L37.1 7.1]
dose escalation and expansion phases.
R, tumour-to-blood ratio; IQR, interquartile range.
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is likely to result in improved tumour radiation
response. This is supported by the observation that high
FMISO uptake in patients with NSCLC is associated
with significantly worse outcomes after radiotherapy
[18]. Furthermore, given that PI3K inhibition is known
to improve tumour intrinsic radiosensitisation, the ef-
fects would be anticipated to be more pronounced than
through hypoxia reduction alone. Encouragingly, early
phase studies combining inhibitors of downstream sig-
nalling targets of PI3K with radiotherapy, such as the
AKT inhibitor nelfinavir, have reported promising
response rates and outcomes in rectal and pancreatic
cancer [26e28]. Hahn et al. demonstrated that upstream
inhibition of Ras with a farnesyltransferase inhibitor
resulted in impressive complete response rates in
NSCLC and head and neck cancer when combined with
radical radiotherapy [29].
Although, we observed a reduction in tumour hyp-
oxia in most patients, this did not always correspond
with increased tumour perfusion. This may reflect the
technical challenges of performing pCT in our patient
population, namely tumours were often only partly
imaged because of large size with significant motion
artefact. Interestingly, this may also perhaps represent
the fact that buparlisib inhibits tumour mitochondrial
oxygen consumption [14], and so changes in hypoxia
and perfusion may, at least in part, be independent
phenomena. In fact, mathematical modelling suggests
that reducing oxygen consumption may be more effec-
tive in addressing tumour hypoxia compared with stra-
tegies aimed solely at improving oxygen delivery [30].
5. Conclusion
Overall, the results from this trial demonstrate that
PI3K inhibition reduces tumour hypoxia in patients
with NSCLC and when combined with thoracic radio-
therapy is well tolerated. This study supports the
development of clinical trials combining this class of
agent with radical radiotherapy with the aim of
improving outcomes in NSCLC.
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